epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Uribel
    methenamine/ sodium phosphate/ phenyl salicylate/ methylene blue/ hyoscyamine
  • remove Vyleesi
    bremelanotide

multicheck MultiCheck Results - 0 Interaction

Smiley face Smiley face

Additional Considerations

Smiley face Smiley face bremelanotide in Vyleesi

avoid combo with oral drugs requiring quick onset and/or efficacy dependent on threshold concentrations; bremelanotide delays gastric emptying, may reduce rate and extent of oral drug absorption

Smiley face Smiley face hyoscyamine in Uribel

caution advised with concurrent oral drugs requiring rapid onset; hyoscyamine delays gastric emptying, may alter absorption of concomitant oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback Cookie Preferences
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information